ClinConnect ClinConnect Logo
Search / Trial NCT04398719

CBD-Microglia PET Study

Launched by YALE UNIVERSITY · May 19, 2020

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Control Pet Scan Mri Scan Central Pain Sensitization Cannabidiol

ClinConnect Summary

The CBD-Microglia PET Study is a research trial that is looking into how a compound called cannabidiol (CBD) affects the activity of certain brain cells known as microglia in healthy individuals. Microglia play an important role in brain health, and the study also wants to see if CBD can influence how the body processes pain. This trial is currently recruiting participants who are between the ages of 18 and 55 and are in good health, meaning they do not have serious medical issues or implanted metal devices that could interfere with MRI scans.

If you decide to participate, you will be asked to undergo some tests to ensure you meet the eligibility requirements. It's important to note that those currently taking medications, pregnant, or breastfeeding cannot take part in the study. Participants will provide written consent and can expect to learn more about how CBD might impact brain function and pain sensitivity. This is an early-stage study, so your involvement could help researchers better understand the potential effects of CBD in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Men and women aged 18- 55 years
  • 2. No significant medical or neurological illness
  • 3. No implanted metal devices that may pose a risk during MRI scanning
  • 4. Within the annual permissible radiation exposure
  • 5. Able to provide written informed consent.
  • Exclusion Criteria:
  • 1. Current use of any medications
  • 2. Presence of metal in the body
  • 3. Pregnancy or lactation

About Yale University

Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.

Locations

New Haven, Connecticut, United States

Patients applied

0 patients applied

Trial Officials

Mohini Ranganathan, MD

Principal Investigator

Yale University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials